ArticleAntimicrobial agents and chemotherapy2011
Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- The fitness connection of antibiotic resistance.Frontiers in microbiology · 2025Article
- Potential effectiveness of parenteral nemonoxacin in the treatment ofFrontiers in microbiology · 2024Article
- Phylogenomic analysis of Clostridioides difficile ribotype 106 strains reveals novel genetic islands and emergent phenotypes.Scientific reports · 2020Article
- Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia.Infection and drug resistance · 2020Article
- Novel Antimicrobials for the Treatment ofFrontiers in medicine · 2018Review
- Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenicInfection and drug resistance · 2018Article
- Molecular Characterization ofFrontiers in microbiology · 2018Article
- Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria.Frontiers in microbiology · 2017Review
- Dissimilar Fitness Associated with Resistance to Fluoroquinolones Influences Clonal Dynamics of Various Multiresistant Bacteria.Frontiers in microbiology · 2016Review
- Predominance of Clostridium difficile Ribotypes 017 and 078 among Toxigenic Clinical Isolates in Southern Taiwan.PloS one · 2016Article
- Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.Antibiotics (Basel, Switzerland) · 2015Review
- Investigation of toxin gene diversity and antimicrobial resistance ofBiomedical reports · 2014Article
- Nemonoxacin: first global approval.Drugs · 2014Review
- Molecular epidemiology of Clostridium difficile strains from nosocomial-acquired infections.Folia microbiologica · 2014Article
- Review of nemonoxacin with special focus on clinical development.Drug design, development and therapy · 2014Review
- Molecular epidemiology of Clostridium difficile infection in a major chinese hospital: an underrecognized problem in Asia?Journal of clinical microbiology · 2013Article
- Characteristics of patients with Clostridium difficile infection in Taiwan.Epidemiology and infection · 2013Article
- Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.Iranian Red Crescent medical journal · 2013Article
- Epidemiology of Clostridium difficile infection in Asia.Antimicrobial resistance and infection control · 2013Article
- Characterization of a stable, metronidazole-resistant Clostridium difficile clinical isolate.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antimicrobial susceptibility and virulence factors of Clostridium difficile clinical isolates in Taiwan have not previously been reported. One hundred and thirteen isolates were collected from two major teaching hospitals in Taiwan from 2001 to 2009. Molecular typing was performed by an automated repetitive extragenic palindromic sequence-based PCR (rep-PCR) method (DiversiLab; Bacterial Barcodes, Inc., Athens, GA) and PCR ribotyping. Detection of tcdA, tcdB, cdtA, and cdtB genes was performed using a multiplex PCR assay, and gyrA and gyrB genes of moxifloxacin-nonsusceptible isolates were sequenced. All isolates were susceptible to vancomycin and metronidazole. Ninety-five (84%) isolates were susceptible to moxifloxacin, and the MIC(90) for nemonoxacin was 4 μg/ml. Tigecycline showed favorable antibacterial activity (MIC(90) of 0.06 μg/ml). Thirteen rep-PCR types were identified as a predominant rep-PCR type (type A; non-North American pulsed-field gel electrophoresis type 1 [NAP1], -NAP7, or -NAP8) accounting for 52.2% (59 isolates). Nine of 18 moxifloxacin-nonsusceptible isolates belonged to the rep-PCR type A. The rep-PCR type A and C isolates were distinct from NAP1 (ribotype 027) and NAP8 (ribotype 078) as determined by PCR ribotyping. Seventy-four (65%) isolates harbored tcdA and tcdB, and 15 (13%) harbored cdtAB encoding binary toxin. Eleven isolates had a gene deletion in tcdC, including a 39-bp deletion (9 isolates) and an 18-bp deletion (2). In conclusion, dissemination of a predominant C. difficile clone in southern and northern Taiwan was noted. However, no NAP1 (ribotype 027) isolate could be discovered in this study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.